Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.
Abstract: An early detection of tomato leaf diseases is crucial for ensuring high-quality and abundant crop production. There is a growing need for an Android application that can identify these ...
That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).
For more than a decade, I have worked as a physician and public-health expert responding to infectious diseases around the world. In 2014, while treating Ebola patients in Guinea, I contracted and ...
Abstract: Bean rust and angular leaf spot pose significant challenges to bean cultivation, impacting yields. Prompt disease identification maximizes productivity, but traditional methods need ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...
Bacterium malvacearum, the causative agent of ‘black-arm’, or angular leaf-spot disease of the cotton plant, has been described in certain recent papers as capable of producing a systemic ...
Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.
Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.
A UK startup that wants to bring protein degraders to the neurodegeneration field has closed a $31 million seed round.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback